Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Refractory K-RAS Mutated CRC (MUTEX)
NCT01450319Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2011
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in colorectal cancer (CRC), sponsored by Merck KGaA. Started Dec 2011; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01450319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450319.